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Abstract
Objective: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV)
mortality. Since CD40-CD154 binding has direct consequences on inflammation process initiation, we aimed to replicate
previous findings related to disease susceptibility in Spanish RA population. Furthermore, as the major complication in RA
disease patients is the development of CV events due to accelerated atherosclerosis, and elevated levels of CD40L/CD154
are present in patients with acute myocardial infarction, we assessed the potential association of CD40 and CD154/CD40L
gene variants with CV risk in Spanish RA patients.
Methods: One thousand five hundred and seventy-five patients fulfilling the 1987 ACR classification criteria for RA and 1600
matched controls were genotyped for the CD40 rs1883832, rs4810485 and rs1535045 and CD154 rs3092952 and rs3092920
gene polymorphisms, using predesigned TaqMan single nucleotide polymorphism genotyping assays. Afterwards, we
investigated the influence of CD40-CD154 gene variants in the development of CV events. Also, in a subgroup of 273
patients without history of CV events, we assessed the influence of these polymorphisms in the risk of subclinical
atherosclerosis determined by carotid ultrasonography.
Results: Nominally significant differences in the allele frequencies for the rs1883832 CD40 gene polymorphism between RA
patients and controls were found (p= 0.038). Although we did not observe a significant association of CD40-CD154 gene
variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography
assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant
association (p= 0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of
atherosclerosis.
Conclusion: Data from our pilot study indicate a potential association of rs1883832 CD40 gene polymorphism with
susceptibility to RA. Also, the CD40 rs1535045 gene variant may influence development of subclinical atherosclerosis in RA
patients.
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Introduction
Rheumatoid arthritis (RA), the prototype of inflammatory
chronic disease, is characterized by a consistent increase of
cardiovascular (CV) mortality and morbidity, mainly due to a
process of accelerated atherosclerosis [1,2,3]. There is some
evidence supporting that both immune dysregulation and a
systemic inflammatory milieu predating and characterizing earlier
phases of RA may be important pathogenic factors of vascular
impairment in patients with this condition. Interesting findings
arise from the observation that CD40–CD40 ligand (CD40L/
CD154) interaction, a crucial step in autoimmune disease
pathogenesis, is thought to be involved in atherogenesis and
plaque rupture in RA [4].
Once that CD40 interacts with its ligand (CD40L, aka CD154)
on T cells, it acts as a transmembrane signal transducer leading to
activation of intracellular kinases and transcription factors, giving
rise to inflammatory responses [5]. CD40 signalling has been
linked to pathogenic processes of chronic inflammatory and
autoimmune diseases [6]. As a consequence of CD154/CD40L
binding to CD40, release of cytokines and expression of adhesion
molecules, as well as numerous inflammatory processes are
triggered [7]. In addition, CD40/CD154 interactions may induce
the expression of matrix metalloproteinases that degrade compo-
nents of the atherosclerotic plaques and promote neovasculariza-
tion, instability and plaque rupture leading to acute CV events or
sudden death [8] and can play a prominent role in thrombotic
events after plaque rupture [5]. This is relevant as the main cause
of mortality and morbidity of RA is atherosclerosis, driving to CV
events that are preceded by subclinical atherosclerosis.
CD40 is a 45–50 kDa membrane glycoprotein, member of the
TNF-receptor superfamily, which acts as a receptor for CD154.
CD40 has been reported to be constitutively and/or inducibly
expressed on B cells, platelets, monocytes and macrophages,
endothelial cells, smooth muscle cells, mast cells, fibroblasts,
dendritic cells, neutrophils and T cells [9] and also in the synovial
fluid of RA patients [10].
A Genome Wide Association Study and meta-analysis high-
lighted the role of the major allele of the rs4810485 CD40
polymorphism on chromosome 20q13 in the susceptibility to RA
[11,12]. Further replication studies in different populations
[13,14,15] confirmed this association. Moreover, a recent report
disclosed that the rs4810485 CD40 variant may affect CD40
mRNA and protein expression on B cells and monocytes [16], and
is in high linkage disequilibrium (r2 = 0.95) with rs1883832, which
has been shown to influence the efficiency of CD40 protein
translation by disrupting a Kozak sequence [17], a stretch of
nucleotides that flanks the start codon important for the initiation
of translation of a nascent mRNA molecule [18]. Indeed, the
major allele of rs1883832 increases the translational efficacy of
CD40 transcripts, resulting in a 15–32% increase in CD40 protein
production [19]. Furthermore, major alleles of rs4810485 and
rs1883832 CD40 genetic variants are associated with Grave’s
disease (GD) [17]; and also minor alleles have been associated with
multiple sclerosis [20,21], Crohn’s disease [20] and giant cell
arteritis [22], although with relatively weak statistical evidence.
CD154, also known as CD40L or TNFSF5, is a 39 kDa
transmembrane protein with particular importance in T-cell
dependent humoral immune responses. CD154 is expressed on
various cell types, including cell types present in atherosclerotic
plaques such as endothelial cells, monocytes, macrophages and
smooth muscle cells [23]. Increased levels of soluble CD154
(sCD154) have been found in patients with systemic lupus
erythematosus (SLE), RA, and Sjo¨gren’s syndrome in association
with disease activity [24]. Moreover, serum levels of sCD154 are
higher in patients with RA than in healthy individuals and they
correlate with both IgM-RF and IgG-RF titers [25]. Located in
chromosome Xq26, CD154 23459A.G (rs3092952) variant has
been reported to influence CD40L plasma levels, and those levels
above median seem to reflect a prothrombotic state which can be
managed with the use of antithrombotic treatment [26]. Also,
rs3092920 CD154 polymorphism is in high linkage disequilibrium
(r2 = 0.97) with a microsatellite located in 39-UTR that has been
associated in Spanish population with SLE [27], another
autoimmune disease associated with accelerated atherosclerosis
and increased risk of CV complications, and with RA susceptibility
[28]. sCD40L is associated with measures of subclinical athero-
sclerosis in the general population [8], and increased levels of
sCD40L have been found in patients with acute myocardial
infarction (MI) and unstable angina [7]. The role of the CD40L in
the susceptibility to autoimmune diseases has not been investigated
as broadly as the CD40, mainly due to this gene being located on
the 6 chromosome. The different prevalence of some of
autoimmune diseases between both genders [29] can suggest that
genes located on the6chromosome could be susceptibility factors
in these diseases; however, few studies analyzing polymorphisms
on this chromosome has been made. Mutations on CD40L gene
are associated with X-Linked Hyper-IgM syndrome; a family
genetic disorder characterized by an increase of IgM level and a
decrease of IgG and IgA [30]; other mutations and/or altered
expression of CD40L, common c chain, FOXP3 (forkhead box P3)
among other genes encoded on the6chromosome, are known to
be cause of immune disorders such as X-SCID and IPEX
dramatically manifested in men, while females can compensate or
reduce severity of the symptoms due to the second6chromosome.
Taking together all these considerations, in the present study we
aimed to confirm the role of CD40 polymorphisms in the
susceptibility to RA in Spanish population. In a second step, we
assessed whether polymorphisms in CD40-CD154 genes may
influence the susceptibility to CV disease in RA. For this purpose,
we analyzed the implication of these polymorphisms in the risk of
CV events and presence of subclinical atherosclerosis in RA.
Results and Discussion
Information on the main demographical data, clinical charac-
teristics of the RA patients (n = 1575) enrolled in the current study,
CV risk factors and CV events of patients is shown in Table 1.
Two hundred and ninety (18.41%, 114 men and 176 women) of
these 1575 RA patients experienced clinically evident CV events:
ischemic heart disease, heart failure, cerebrovascular accident or
peripheral arteriopathy.
Patients with CV events were older at the time of disease
diagnosis, were more likely to be men and more often had
hypertension, diabetes mellitus, dyslipidemia and obesity. More-
over, smoking habit (defined as those patients who smoked at the
time of disease diagnosis, during the follow-up or who had smoked
within the 10 years before the onset of RA symptoms or the disease
diagnosis) was more frequent in men than in women RA patients
(44.76% vs. 22.82%). Epidemiological studies have shown that
among environmental factors, cigarette smoking is one of the most
relevant causes involved in RA pathogenesis [31,32,33,34,35]. It
seems to play a relevant role in disease induction and progression,
particularly in predisposed individuals [36]. On the other hand, a
recent study has disclosed that circulating levels of sCD40L are
increased in smokers during the early phase of acute MI [37],
although number of patients involved was small. Also, although in
some studies there was a synergist effect of smoking and genetic
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factors on the increased risk of cardiovascular disease of patients
with rheumatoid arthritis, in our population we found no additive
effect of smoking and CD40-CD154 gene polymorphisms (data not
shown).
Genotyping success rate was.95% overall. The estimated
statistical power of the study to detect genetic modest effects like
OR 1.17 in our cohort, was.75% for rs1883832, rs4810485 and
rs1535045 CD40 polymorphisms; and 80% (in women population)
and 46% (men) for rs3092952 and 63% (women) and 35% (men)
for rs3092920 to detect an OR = 1.25 in the case of CD154
polymorphisms, assuming a prevalence of RA in Spanish
population (0.5%) [38], under the condition of a error 0.05 and
b error 0.20.
The statistical power of this study to detect a difference between
absence or presence of CV disease in RA patients with an
estimated OR 1.25, a type I error rate of 0.05, type II error rate of
0.20, and 0.05% of population risk, was 61% for CD40 single
nucleotide polymorphisms (SNPs) and between 48% (male) and
53% (female patients) for the rs3092952 polymorphism and
between 34% (male) and 36% (female) for the rs3092920 CD154
gene variant.
Minor Allele Frequencies of the CD40 rs1883832,
rs4810485 and rs1535045, and CD154 rs3092952 and
rs3092920 Polymorphisms in RA Patients and Controls
Genotype frequencies were conformed to Hardy-Weinberg
equilibrium (p.0.05) both in patients and controls for all genetic
variants under study.
A nominally significant difference in the allele frequency of the
CD40 rs1883832 gene polymorphism between RA patients and
controls was seen (p= 0.038), supporting a role of this CD40
59UTR variant in the susceptibility to RA in Spanish population
(Table 2). On the other hand, CD40 rs4810485 variant was
marginally associated with disease susceptibility (p= 0.069).
However, no association or trend was detected when allele or
genotype frequencies of the CD40 rs1535045 polymorphism in RA
patients were compared with those observed in controls (Table 2).
Allele frequencies observed for rs1883832 and rs4810485 CD40
genetic polymorphisms (27.7% and 27.2%, respectively) were
slightly different from those reported in HapMap CEU population
(22.5% and 23%, respectively). The rs1535045 allele frequency
(24.7%) was similar to the reported in HapMap CEU population
(25%).
Because CD154 is located on the 6 chromosome, and the
elevated incidence of RA in women and higher frequency of
atherosclerosis in men, we compared allele frequencies between
patients and controls in males and females separately. No
association was found between the CD154 gene variants and
susceptibility to RA disease (Table 2). Allele frequencies observed
for rs3092952 and rs3092920 CD154 gene variants (17.2% and
11.1%) were somewhat different from those reported in HapMap
for CEU population (23% and 8%, respectively).
CD40 and CD154 Variants and Risk of CV Events in
Patients with RA
Table 2 shows the genotype frequencies of the CD40
rs1883832, rs4810485 and rs1535045 gene polymorphisms in this
series of RA patients stratified according to the presence or
absence of CV events. No association was found between CD40
polymorphisms and CV events risk in our RA patients cohort. It
was also the case for CD154 gene variants in women or men RA
patients.
Table 1. Clinical and demographic characteristics of rheumatoid arthritis (RA) patients included in the study, stratified by gender
or by Cardiovascular events.
Total Males, N (%) Females, N (%) With CV events, N (%) Without CV events, N (%)
RA Patients 1575 407 (25.84) 1168 (74.16) 290 (18.41) 1285 (81.59)
Age of patients at the time of disease diagnosis,
years, median (IQR)
54 (43–64) 57 (46–68) 53 (42–63) 62.4 (53–73) 52 (41–61)
Time follow up, years, median (IQR) 10.8 (5.5–17) 9.7 (5.5–15) 11 (5.5–18) 11 (6–19) 10.59 (5–16.7)
Anti-CCP positive (n = 1285) 745 (57.98) 185 (57.99) 567 (58.69) 112 (52.83) 633 (58.99)
Rheumatoid Factor positive (n = 1548) 1078 (69.64) 281 (71.14) 797 (69.12) 188 (69.63) 890 (69.64)
Shared epitope, presence (n = 1230) 773 (62.85) 212 (64.05) 561 (62.40) 155 (64.05) 618 (62.55)
Cardiovascular events 290 (18.41) 114 (28.09) 176 (15.06) 290 (18.41) -
Ischemic heart disease 152 (9.6) 74 (18.33) 78 (6.68) 152 (9.6) -
Cerebrovascular accidents* 78 (4.97) 27 (6.73) 51 (4.36) 78 (4.97) -
Heart failure 84 (5.5) 16 (4.07) 68 (6.02) 84 (5.5) -
Peripheral arteriopathy 36 (2.36) 15 (3.81) 21 (1.85) 36 (2.36) -
Hypertension (n = 1565) 540 (40.89) 169 (42.14) 471 (40.46) 202 (67.33) 438 (34.62)
Diabetes mellitus (n = 1560) 206 (13.21) 66 (16.58) 140 (12.05) 73 (24.41) 133 (10.51)
Dyslipidemia (n = 1561) 616 (39.46) 143 (35.57) 473 (40.81) 167 (55.30) 449 (35.66)
Obesity (n = 1480) 345 (23.31) 84 (22.52) 261 (23.58) 81 (29.14) 264 (21.96)
Smoking habit** (n = 1495) 425 (28.43) 171 (44.76) 254 (22.82) 94 (32.64) 331 (27.42)
Except where indicated otherwise, values are n (%). IQR: Interquartile Range. Anti-CCP: anti-Cyclic Citrullinated Peptide antibodies.
*A patient was considered to have a cerebrovascular accident when he/she had a stroke and/or transient ischemic attacks (TIAs). Strokes were classified according to
their clinical features and they were confirmed by computed tomography and/or magnetic resonance imaging. TIAs were diagnosed if the symptoms were self-limited
in less than 24 hours, without residual neurological damage [41].
**Smoking habit encompassed to those patients who smoked at the time of disease diagnosis, during the follow-up or who had smoked within the 10 years before the
onset of RA symptoms or the disease diagnosis.
doi:10.1371/journal.pone.0049214.t001
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Logistic regression model to determine the presence of CV
disease in RA patients according to CD40 rs1883832, rs4810485
and rs1535045 allele distribution did not disclose statistically
significant differences between patients who suffer CV events
against the ones who did not (Table S1). The same model was
applied for the CD154 variants, stratifying patients by gender, and
no association was detected (Table S2). Analyses were adjusted
for sex, age at RA diagnosis, follow-up time and presence or
absence of shared epitope, hypertension, diabetes mellitus,
dyslipidemia, obesity and smoking habit as confounder factors.
In addition, we specifically assessed the influence of the variants in
the occurrence of cardiac ischemic events, heart failure or
cerebrovascular accidents. However, no significant association
was found (data not shown), despite the fact that CD154
23459A.G (rs3092952) variant has been reported to influence
CD40L plasma levels, although the 23459 G allele did not confer
an increased risk of MI or mortality in the general population [26].
However, the CD40/CD154 system is involved in the increased
inflammatory response and extracellular matrix degradation [39],
leading to disruption of atherosclerotic plaque [40].
In a further step, to assess the independency of the polymor-
phisms in their association with clinically evident CV disease, we
performed a conditional logistic regression analysis. However, no
significant association was observed for them (Tables S3 and S4),
although a trend of association was found between CD154
rs3092952 and rs3092920 variants in women after correction of
the conditional analysis by age at RA diagnosis, follow-up time
and presence or absence of shared epitope, and traditional
cardiovascular risk factors as confounders.
No epistatic interactions of the CD40 polymorphisms with HLA-
DRB1-shared epitope [41] were observed (data not shown).
Likewise, no significant associations were detected when we
analyzed our cohort of patients by presence or not of hypertension,
diabetes mellitus, dyslipidemia or anti-Cyclic Citrullinated Peptide
antibodies (anti-CCP) status (data not shown).
Table 2. Genotype and minor allele frequencies of SNPs located within CD40 (20q13) and CD40L (Xq26) genes in RA Spanish
patients and healthy controls.
GENOTYPE, N (%) ALLELE TEST
Locus Gene SNP 1/2 Subgroup 1/1 1/2 2/2 MAF p-valuea OR [95% CI]b
20q12 CD40 rs1883832 C/T CONTROLS (n = 1545) 814 (52.69) 607 (39.29) 124 (8.02) 0.277
RA (n = 1510) 839 (55.56) 577 (38.21) 94 (6.23) 0.253 0.038 0.89 [0.79–0.99]c
without CV events (n = 1227) 685 (55.83) 464 (37.82) 78 (6.36) 0.253
with CV events (n = 283) 154 (54.42) 113 (39.93) 16 (5.65) 0.256 0.86 1.02 [0.82–1.26]d
20q12 CD40 rs4810485 G/T CONTROLS (n = 1548) 828 (53.49) 597 (38.57) 123 (7.95) 0.272
RA (n = 1503) 839 (55.82) 571 (37.99) 93 (6.19) 0.252 0.069 0.90 [0.80–1.01]c
without CV events (n = 1219) 686 (56.28) 457 (37.49) 76 (6.23) 0.25
with CV events (n = 284) 153 (53.87) 114 (40.14) 17 (5.99) 0.26 0.59 1.06 [0.85–1.31]d
20q12 CD40 rs1535045 C/T CONTROLS (n = 1558) 887 (56.93) 572 (36.71) 99 (6.35) 0.247
RA (n = 1519) 847 (55.76) 579 (38.12) 93 (6.12) 0.252 0.67 1.03 [0.91–1.15]c
without CV events (n = 1236) 684 (55.34) 472 (38.19) 80 (6.47) 0.256
with CV events (n = 283) 163 (57.60) 107 (37.81) 13 (4.59) 0.235 0.31 0.89 [0.72–1.11]d
Xq26.3 CD154 rs3092952 A/G Female CONTROLS (n = 890) 610 (68.5) 246 (27.6) 34 (3.8) 0.176
Females RA (n = 1115) 740 (66.37) 335 (30.04) 40 (3.59) 0.186 0.20 1.11 [0.94–1.31]c
without CV events (n = 943) 621 (65.85) 286 (30.33) 36 (3.82) 0.189
with CV events (n = 172) 119 (69.19) 49 (28.49) 4 (2.33) 0.166 0.29 0.85 [0.62–1.16]d
Male CONTROLS (n = 676) 568 (84.02) – 108 (15.98) 0.160
Male RA (n = 375) 316 (84.27) – 59 (15.73) 0.157 0.93 1.02 [0.71–1.46]c
without CV events (n = 268) 226 (84.33) – 42 (15.67) 0.157
with CV events (n = 107) 90 (84.11) – 17 (15.89) 0.159 0.96 1.02 [0.52–1.95]d
Xq26.3 CD154 rs3092920 G/T Female CONTROLS (n = 878) 707 (80.5) 156 (17.8) 15 (1.7) 0.106
Female RA (n = 1115) 892 (80.00) 209 (18.74) 14 (1.26) 0.106 0.97 1.00 [0.82–1.24]c
without CV events (n = 940) 751 (79.89) 177 (18.83) 12 (1.28) 0.107
with CV events (n = 175) 141 (80.57) 32 (18.29) 2 (1.14) 0.103 0.82 0.96 [0.65–1.41]d
Male CONTROLS (n = 669) 587 (87.74) – 82 (12.26) 0.123
Male RA (n = 374) 339 (90.64) – 35 (9.36) 0.094 0.16 0.74 [0.48–1.14]c
without CV events (n = 269) 242 (89.96) – 27 (10.04) 0.100
with CV events (n = 105) 97 (92.38) – 8 (7.62) 0.076 0.47 0.74 [0.30–1.78]d
aP-value for the allelic model.
bOdds Ratio for the minor allele.
cwith respect to Controls.
dcomparing RA patients with CV events versus RA patients without CV events. MAF: minor allele frequency.
doi:10.1371/journal.pone.0049214.t002
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We also analyzed the combined influence of the CD40
rs1883832 and rs1535045 variants in the risk of CV disease
comparing the frequency of their estimated haplotypes, but no
significant differences were observed among combinations, before
or after adjustment by sex, age, follow-up time or long-established
CV risk factors (Table S5).
In line with the above, the analysis of the combined influence
for CD40L rs3092952 and rs3092920 polymorphisms did not
disclose association between allelic combinations and risk of CV
events. Only three combinations were considered in males; a
fourth combination was excluded from the analysis due to its low
frequency: 1.56% among the subjects without CV disease and 0%
in those with CV disease (Table S5).
CD40 rs1883832, rs4810485 and rs1535045 and CD154
rs3092952 and rs3092920 Gene Polymorphisms and
Subclinical Atherosclerosis
Since carotid intima-media thickness (IMT) has been found to
predict the risk of CV events in the extended follow-up of patients
with RA [42], in a further step we analyzed potential differences in
the carotid IMT in 273 RA patients with no history of CV events
stratified according to the genotype and allele distribution. In this
regard, when we assessed the genotype distribution of the CD40
rs1535045 polymorphism, we observed that RA patients carrying
the CC CD40 rs1535045 genotype (n = 155) had higher carotid
IMT (0.7560.19 mm) than those CT CD40 rs1535045 heterozy-
gous (n = 104; carotid IMT: 0.7260.16 mm) or the homozygous
for the minor T allele CD40 rs1535045 (n = 14; carotid IMT:
0.7060.16 mm). However, these differences in the genotype
distribution did not reach statistical significance. In keeping with
this observation when we assessed allele distribution of the CD40
rs1535045 polymorphism, we observed that RA patients carrying
the C allele of the CD40 rs1535045 gene variant (n = 414) had
higher carotid IMT (0.7460.18 mm) than those carrying the less
common T allele (n = 132; carotid IMT: 0.7160.16 mm).
Nevertheless, differences were not statistically significant
(p = 0.13) (Table 3). It was also the case for the remaining
CD40 gene polymorphisms (Table 3), as well as CD154 gene
variants assessed in the study (Table 4).
Interestingly, when the analysis of variance (ANOVA) model
was adjusted for sex, age at the time of the ultrasonography
assessment, follow-up time, and traditional CV risk factors
(ANCOVA model), we did observe nominally significant evidence
of association between carotid IMT and rs1535045 CD40
polymorphism (p= 0.023) (Table 5); therefore, we carried out a
permutation test with 100000 replications in order to control type
I error; in the permutation test, the relationship between carotid
IMT and rs1535045 CD40 gene variant had p value = 0.048
(estimated with precision lower than 0.001). This result could be
related to the fact that increased CD40 expression has been
established in unstable atherosclerotic plaques [9], and carotid
IMT is one of the parameters well known as a marker of early
atherosclerosis. In addition, CD40 rs1535045 SNP has previously
been reported to be significantly associated with coronary artery
calcification, which correlates with atherosclerosis and CV disease
[39], although the SNP was not previously associated with carotid
IMT. Since presence of anti-CCP antibodies had been previously
associated with stronger evidence of CV disease in patients with
RA [43], in a further step the ANCOVA model was also adjusted
for anti-CCP status, that confirmed the statistically significant
association between rs1535045 CD40 polymorphism and carotid
IMT (p= 0.0047). Conditional analysis of the rs1883832 and
rs1535045 CD40 gene variants in the adjusted ANCOVA model,
rendered following p-values: 0.82 and 0.0047 for rs1883832 and
rs1535045, respectively. No association was found in case of
CD154/CD40L gene variants (Table 6). Our results indicate that
a potential association between surrogate markers of atheroscle-
rosis, in this case carotid IMT, and CD40 rs1535045 polymor-
phism may exist. It may have clinical significance as carotid IMT
has proved to be a good predictor of CV events in patients with
Table 3. Comparison of carotid artery intima-media thickness (cIMT) according to CD40 rs1883832, rs4810485 and rs1535045
polymorphisms.
rs1883832
cIMT mm,
mean (SD) p rs4810485
cIMT mm,
mean (SD) p rs1535045
cIMT mm,
mean (SD) p
CC (n = 143) 0.73 (0.17) GG (n = 143) 0.73 (0.18) CC (n = 155) 0.75 (0.19)
CT (n = 107) 0.74 (0.18) GT (n = 106) 0.74 (0.18) CT (n = 104) 0.72 (0.16)
TT (n = 23) 0.75 (0.16) TT (n = 24) 0.75 (0.16) TT (n = 14) 0.70 (0.16)
Model 0.71 0.82 Model 0.29
C (n = 393) 0.73 (0.18) G (n = 392) 0.73 (0.18) C (n = 414) 0.74 (0.18)
T (n = 153) 0.74 (0.17) 0.41 T (n = 154) 0.74 (0.17) 0.52 T (n = 132) 0.71 (0.16) 0.13
doi:10.1371/journal.pone.0049214.t003
Table 4. Comparison of carotid artery intima-media thickness
(cIMT) according to CD154 rs3092920 and rs3092952 SNPs.
Gender rs3092952
cIMT
mean
(SD) p rs3092920
cIMT
mean
(SD) p
Women AA (n = 130) 0.73
(0.17)
GG (n = 161) 0.72
(0.17)
AG (n = 69) 0.70
(0.14)
GT (n = 37) 0.70
(0.14)
GG (n = 4) 0.80
(0.20)
TT (n = 3) 0.67
(0.02)
Model 0.43 0.65
A (n = 329) 0.72
(0.16)
G (n = 359) 0.72
(0.16)
G (n = 77) 0.71
(0.15)
0.73 T (n = 43) 0.70
(0.13)
0.34
Men A (n = 57) 0.78
(0.21)
G (n = 64) 0.78
(0.21)
G (n = 9) 0.79
(0.24)
0.91 T (n = 4) 0.71
(0.09)
0.46
doi:10.1371/journal.pone.0049214.t004
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RA [42]. Association between endothelial dysfunction, another
surrogate marker of atherosclerosis that is considered an early step
in the atherogenesis process, and other genetic markers has been
reported by other studies in RA patients [44,45,46]. These
findings showing association between markers of subclinical
atherosclerosis and genetic polymorphisms in RA have clinical
relevance as they can help to identify patients at risk before CV
events may occur.
Looking for a relation between rs1535045 CD40 gene variant
and the presence of carotid plaques in patients with carotid
IMT.1.0 mm, we did not find any significant association nor in
the crude (allelic p= 0.71, 95% CI [0.23–1.81]) or adjusted by sex,
age at RA diagnosis, follow-up time and traditional CV factors,
model (allelic p= 0.65, 95% CI [0.23–1.83]), although number of
patients involved was small (n = 19).
As in many other human genetic studies, potential limitations
may exist in our study. In this regard, the phenotypes involved in
the atherosclerosis disease, which some consider an inflammatory
autoimmune disease [47], are complex and involve multiple small-
to modest effects of multiple genes and environmental factors.
Since increased carotid IMT is a surrogate marker of atheroscle-
rosis that may allow identifying high risk patients in a subclinical
phase of the disease, longer duration of follow-up may be required
to see the clinical relevance of the CD40 rs1535045 in the
atherosclerosis disease of patients with RA. In keeping with our
data showing association of subclinical atherosclerosis with CD40
rs1535045 gene variant, a recent study on 681 Swedish patients
with RA disclosed an association between stroke/transient
ischemic accident in men with RA that were homozygous for
the CD40 rs1535045 polymorphism major allele [48]. Regrettably,
although our study encompassed a larger number of patients, we
could not confirm association of any of the CD40 gene
polymorphisms with clinically evident CV events in Spanish RA
patients. There are a number of potential explanations that might
enlighten these differences. First, RA is a complex disease and both
the genetic backgrounds as well as environmental factors have
clearly been shown to influence the phenotype expression of the
disease and its potential complications. Second, the Swedish study
included patients with longer follow-up (mean 15.5 years) from
disease diagnosis than our cohort (median 10.8 years). Since the
carotid IMT has been found to predict the development of CV
events in the extended follow-up of patients with RA [42], a longer
follow-up might be required to disclose a clinical association
between rs1535045 polymorphism in CD40 and CV events in our
population.
In conclusion, our data may indicate a potential association of
the single nucleotide polymorphism located in the 59-UTR of the
CD40 gene (rs1883832, 21C/T) with susceptibility to RA in the
Spanish population. Also, based on our results, a potential
influence of the CD40 rs1535045 variant in the development of
subclinical atherosclerosis in RA patients may exist. However,
given that no other independent cohort was available for
replication; our study should be regarded as a pilot one. Therefore,
further studies in population with different genetic backgrounds
are required to confirm the implication of CD40/CD154 system
in the atherosclerosis process associated to RA.
Materials and Methods
Patients and Controls
Between March 1996 and September 2008,1575 consecutive
patients that fulfilled the 1987 American College of Rheuma-
tology classification criteria for RA [49] were recruited from the
Rheumatology Outpatient Clinics of Hospital Xeral-Calde
(Lugo), Hospital Clı´nico San Carlos (Madrid), Hospital Uni-
versitario La Paz (Madrid), Hospital Universitario La Princesa
(Madrid), Hospital Universitario Marque´s de Valdecilla (San-
tander), and Hospital Universitario de Bellvitge (Barcelona),
Spain. Patients and 1600 bone marrow and blood donors from
National Repository DNA Bank (University of Salamanca,
Spain), matched by age, sex and ethnicity, from the corre-
sponding regions, were assessed for differences in the CD40
rs1883832, rs4810485 and rs1535045, and CD154 rs3092952
and rs3092920 gene variants.
Study Protocol
Ethics Statement. A subject’s written consent was obtained
according to the declaration of Helsinki, and propose of the
work was approved by the Ethics Committee of Galicia (Spain).
The Ethics Committees of the Hospital Clı´nico San Carlos
(Madrid), Hospital La Paz (Madrid), Hospital de La Princesa
(Madrid), Hospital Universitario Bellvitge (Barcelona) and
Hospital Universitario Marque´s de Valdecilla (Santander) also
approved the study.
Between December 2009 and January 2010 patient’s clinical
records were examined until patient’s death, loss of follow-up or
Table 5. Comparison of carotid intima-media thickness (cIMT)
according to CD40 rs1883832, rs4810485 and rs1535045
alleles in an adjusted ANCOVA model.
cIMT
CD40 rs1883832, p T vs. C* 0.62
CD40 rs4810485, p T vs. G* 0.63
CD40 rs1535045, p T vs. C* 0.023
CD40 rs1883832, p T vs. C**{ 0.59
CD40 rs1535045, p T vs. C**{ 0.023
*Analyses adjusted for sex, age at rheumatoid arthritis diagnosis, follow-up
time, and traditional cardiovascular risk factors.
**Conditional analysis of the rs1883832 and rs1535045 CD40 gene variants.
{Analyses adjusted for sex, age at rheumatoid arthritis diagnosis, follow-up
time, traditional cardiovascular risk factors and anti-CCP status: p= 0.82 and
0.0047 for rs1883832 and rs1535045, respectively.
doi:10.1371/journal.pone.0049214.t005
Table 6. Comparison of cIMT according to CD154 rs3092952
and rs3092920 alleles in an adjusted ANCOVA model,
stratified by gender.
Gender cIMT
Women CD154 rs3092952, p G vs. A* 0.62
CD154 rs3092920, p T vs. G* 0.89
CD154 rs3092952, p G vs. A** 0.30
CD154 rs3092920, p T vs. G** 0.47
Men CD154 rs3092952, p G vs. A* 0.91
CD154 rs3092920, p T vs. G* 0.28
CD154 rs3092952, p G vs. A** 0.96
CD154 rs3092920, p T vs. G** 0.32
*Analyses adjusted for age at rheumatoid arthritis diagnosis, follow-up, and
classic CV risk factors and anti-CCP status.
**Conditional analysis of the rs3092952 and rs3092920 CD154 gene variants.
doi:10.1371/journal.pone.0049214.t006
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December 1st, 2009. Information on the main demographic
characteristics, CV risk factors and CV events of RA patients is
shown in Table 1. Clinical definitions for CV events and classic
CV risk factors were described elsewhere [41,42,50]. A CV event
was considered to be present if the patient had ischemic heart
disease, heart failure, cerebrovascular accident or peripheral
arteriopathy.
DNA was obtained from patients peripheral blood, using
standard methods.
Genotyping
CD40 and CD154 genotyping. Subjects were genotyped to
determine:
*Three SNPs of CD40 associated with other autoimmune
diseases: rs1883832 located in the Kozak consensus sequence of
the 59-UTR, had been associated with GD [19]; while rs4810485,
located in the first intron of the gene and in high linkage
disequilibrium with rs1883832 (r2 = 0.95), has been identified as a
risk factor for RA [11]. Moreover, the major allele of rs1535045
SNP, located in the first intron of the gene, has been associated
with subclinical atherosclerosis in diabetes families [39].
*Two genetic variants located in 59 UTR (rs3092952) and 39
UTR (rs3092920) of CD40L (r2 = 0.38) were selected. These SNPs
are located in different haplotype blocks of CD40L [51]. The
variant rs3092920 is located near to 39-UTR microsatellite, which
was previously associated with RA and SLE [27,28]; while
rs3092952 is a functional variant related with the levels of
sCD40LG in plasma [26].
CD40 and CD154 variants genotyping were made using
TaqMan Assays-on-Demand and TaqMan Genotyping Master
Mix, and analyzed using the ABI 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA), following
manufacturer instructions. Negative controls and duplicates were
included to check the accuracy of the genotyping.
Shared Epitope determination. Several HLA-DRB1 alleles
(HLA-DRB1*0401, *0404, *0405, *0408, *0101, *0102, *1001,
*1402) are associated with susceptibility to RA. These alleles
encode a conserved amino acid sequence called the shared
epitope, at position 70–74 in the third hypervariable region of the
HLA-DRb1 molecule [52]. HLA-DRB1 typing was carried out
using a reverse dot-blot kit with sequence-specific oligonucleotide
(SSO) probes (Dynal RELITM SSO HLA-DRB1 typing kit;
Dynal Biotech, Bromborough, UK).
Assessment of Carotid Plaque and Carotid Intima Media
Thickness (IMT)
To determine the potential association between the CD40/
CD154 (CD40L) polymorphisms and the presence of subclinical
atherosclerosis, between March 2007 and September 2010 a
random subgroup of patients (n = 273) with no previous history
of CV events was assessed by carotid ultrasonography to
determine the carotid IMT and carotid plaques [53,54]. The
common carotid arteries (CCAs) were evaluated with high
resolution B-mode ultrasound (SONOS5500 and IE33, Philips
Medical Systems, Andover, MA, USA) using a linear array 11-
MHz probe with a standardized setup. Carotid IMT was
measured at the posterior wall of the right and left CCAs,
10 mm from the carotid bifurcation, over the proximal 10-mm-
long segment. The patients were placed in the supine position
with their heads slightly bent in the opposite direction from the
examination side. The right and left CCAs was first identified in
B-mode, in a transverse view and followed from the proximal
part to the bulb origin. Immediately afterwards, the CCAs and
the most proximal part of the bulb were imaged in a
longitudinal view from a lateral approach. Both common
carotid arteries were scanned longitudinally to visualize the
intima-media complex of the far wall of the artery. The
segments of the CCAs 10 mm proximal to the carotid
bifurcation were scanned. The image was focused on the
posterior carotid wall in longitudinal view. For measurement of
the IMT, the distance between the leading edges of the lumen-
intima interface and the media-adventitia interface of the B-
mode frame was taken. The IMT was calculated for both the
left and the right CCA, and the CCA-IMT was defined as the
maximum of these. An ECG recording during the ultrasound
examination was obtained for all patients. All measurements
were performed in the end-diastole. Carotid plaque was
considered to be present when there was a localized irregular
thickening of at least 1.5 mm.
Statistical Analysis
All genotype data were checked for deviation from Hardy-
Weinberg equilibrium (HWE) using http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl.
Comparison of proportions was carried out using x2 test or
Fisher test, when required. Strength of associations between CV
events and genotypes or alleles of CD40 and CD154 variants were
estimated using odds ratios (OR) and 95% confidence intervals
(CI), via multiple logistic regression; estimates were further
adjusted by sex, age at RA diagnosis, time of follow-up, presence
or absence of the rheumatoid shared epitope, and classic CV risk
factors (hypertension, diabetes mellitus, dyslipidemia, obesity and
smoking habit) as potential confounders. Given CD40LG is located
on the X-chromosome and the sex bias of RA disease, we
performed the analysis separately to each gender for those gene
variants.
The association between genotypes of the CD40 and CD154
SNPs and carotid IMT as surrogate marker of subclinical
atherosclerosis were tested using unpaired t test to compare
between 2 groups, and one-way analysis of variance (ANOVA) to
compare among more than two groups. Moreover, we also tested
the association between these parameters and alleles using analysis
of covariance (ANCOVA) adjusting for gender, age and duration
of the disease at the time of the ultrasonographic study, traditional
CV risk factors, and anti-CCP status.
Nominal statistical significance was defined as p,0.05. Statis-
tical significance, after applying a Bonferroni adjustment for 4
independent SNPs, was p,0.0125. We carried out a permutation
test with 100,000 replications in order to control type I error, using
the programme Stata 12/SE (StataCorp, College Station, TX,
USA).
Statistical power for the study was calculated using ‘‘CaTS -
Power Calculator for Two Stage Association Studies’’ (http://
www.sph.umich.edu/csg/abecasis/CaTS/) [55].
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